Cardiology

Cardiology

By ReachMDMedicine
Download on the App Store

Cardiology episodes

  • When and Why to Use CAC Scoring
    Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
    Guest: Rishi Wadhera, MD, MPP, Mphil

    Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

    5 min
  • Albuminuria Change and Finerenone's Effect on CV Outcomes
    Guest: Finnian R. McCausland, MD

    These video briefs feature expert commentary on the latest clinical data presented at ERA 2025 and highlight finerenone’s evolving role in the care of patients with the cardio-kidney-metabolic syndrome. Specialists discuss new findings from the CONFIDENCE trial and FINEARTS-HF trial, including the efficacy and safety of combining finerenone with SGLT2 inhibitors, finerenone’s impact on eGFR slope across albuminuria levels, and the prognostic significance of albuminuria reduction. The series delves into the mechanistic rationale, therapeutic implications, and real-world potential of nonsteroidal MRAs in managing patients with chronic kidney disease, type 2 diabetes, and heart failure. Viewers will gain practical insights on integrating these data into their clinical practice to improve patient outcomes.

    3 min
  • Topline Results of the CONFIDENCE Trial
    Guest: Rajiv Agarwal, MBBS, MD, FASN, BRCU

    These video briefs feature expert commentary on the latest clinical data presented at ERA 2025 and highlight finerenone’s evolving role in the care of patients with the cardio-kidney-metabolic syndrome. Specialists discuss new findings from the CONFIDENCE trial and FINEARTS-HF trial, including the efficacy and safety of combining finerenone with SGLT2 inhibitors, finerenone’s impact on eGFR slope across albuminuria levels, and the prognostic significance of albuminuria reduction. The series delves into the mechanistic rationale, therapeutic implications, and real-world potential of nonsteroidal MRAs in managing patients with chronic kidney disease, type 2 diabetes, and heart failure. Viewers will gain practical insights on integrating these data into their clinical practice to improve patient outcomes.

    5 min
  • The CONFIDENCE Trial: Data Insights
    Guest: prof. Hiddo Heerspink

    These video briefs feature expert commentary on the latest clinical data presented at ERA 2025 and highlight finerenone’s evolving role in the care of patients with the cardio-kidney-metabolic syndrome. Specialists discuss new findings from the CONFIDENCE trial and FINEARTS-HF trial, including the efficacy and safety of combining finerenone with SGLT2 inhibitors, finerenone’s impact on eGFR slope across albuminuria levels, and the prognostic significance of albuminuria reduction. The series delves into the mechanistic rationale, therapeutic implications, and real-world potential of nonsteroidal MRAs in managing patients with chronic kidney disease, type 2 diabetes, and heart failure. Viewers will gain practical insights on integrating these data into their clinical practice to improve patient outcomes.

    4 min
  • Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF
    Guest: Finnian R. McCausland, MD

    These video briefs feature expert commentary on the latest clinical data presented at ERA 2025 and highlight finerenone’s evolving role in the care of patients with the cardio-kidney-metabolic syndrome. Specialists discuss new findings from the CONFIDENCE trial and FINEARTS-HF trial, including the efficacy and safety of combining finerenone with SGLT2 inhibitors, finerenone’s impact on eGFR slope across albuminuria levels, and the prognostic significance of albuminuria reduction. The series delves into the mechanistic rationale, therapeutic implications, and real-world potential of nonsteroidal MRAs in managing patients with chronic kidney disease, type 2 diabetes, and heart failure. Viewers will gain practical insights on integrating these data into their clinical practice to improve patient outcomes.

    4 min
  • Optimizing Barostim Outcomes: Practical Approaches to Patient Selection and Monitoring
    Host: Cynthia J. Bither, ACNP-BC, MSN
    Guest: Andrea Wallace, MSN, FNP-C, HF-Cert

    Medical devices such as Barostim – or baroreflex activation therapy (BAT) – can play an important role in improving the quality of life and providing symptom relief for patients with heart failure with reduced ejection fraction, or HFrEF. NPs and nurses are key members of the healthcare team who identify patients as potential candidates for this therapy, due in large part to their expertise in eliciting symptoms and getting the full picture from patients regarding the impact of HFrEF on their quality of life. As the direct – and oftentimes most frequent – point of contact for patients, advanced care and allied health professionals can lead the way to open and honest communication with the goal of optimizing treatment plans and positively impacting patient outcomes.

    9 min
  • Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
    Guest: prof. Hiddo Heerspink
    Guest: Jennifer B. Green, MD

    Can combining a nonsteroidal MRA and an SGLT2 inhibitor unlock new clinical potential for patients with type 2 diabetes and chronic kidney disease (CKD)? In this expert discussion, Dr. Jennifer Green and Dr. Hiddo Heerspink review the latest findings from the CONFIDENCE trial, which demonstrated a significant additive reduction in albuminuria—an important surrogate marker for kidney and cardiovascular risk—when finerenone and empagliflozin are used together. They explore the clinical rationale behind combination therapy, address persistent challenges in CKD detection, and consider the practical implications for implementing these therapies in high-risk populations.

    16 min
  • Setting the Bar: Guideline-Recommended Treatment in Hypertriglyceridemia
    Guest: Børge G. Nordestgaard, MD, DMSc
    Guest: Kausik Ray, MBChB, MD, MPhil

    There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

    4 min
  • Practical Tips for GLP-1 RA Therapy Success
    Guest: Michael Crotty, MB, BCh, BAO
    Guest: Ana Maria Cebrián-Cuenca, MD, PhD

    This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.

    This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org

    6 min
  • SHTG: Decoding the Latest Clinical Trial Outcomes
    Guest: Pam R. Taub, MD, FACC, FASPC
    Guest: Kausik Ray, MBChB, MD, MPhil

    There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

    5 min